Title:
IMPROVEMENTS IN BENZODIAZEPINE TREATMENT BY CHOLINESTERASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO1992020328
Kind Code:
A3
Abstract:
The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for counteracting the sedative, hypnotic or respiratory depressive effects of benzodiazepines, substantially without interfering with the anxiolytic, antipsychotic, anticonvulsant, and muscle relaxant activity of benzodiazepines, especially the benzodiazepines used for treatment of diseases where the sedative, hypnotic or respiratory depressive effects are undesirable, such as diseases selected from the group consisting of anxiety, anxiety neurosis, anxiety reactions, panic reactions, schizophrenia, affective or schizoaffective type schizophrenia, borderline psychosis, agitating endogene depressions, hyperactivity in children, and muscle spasms. The acetyl cholinesterase is preferably one that acts substantially selectivity at nicotinic receptor sites, and which has selectively for acetyl cholinesterase opposed to butyryl cholinesterase, e.g. galanthamine or a galanthamine derivative.
Inventors:
SNORRASON ERNIR (IS)
Application Number:
PCT/DK1992/000161
Publication Date:
April 15, 1993
Filing Date:
May 14, 1992
Export Citation:
Assignee:
SNORRASON ERNIR (IS)
International Classes:
A61K31/00; A61K31/14; A61K31/27; A61K31/365; A61K31/40; A61K31/407; A61K31/44; A61K31/34; A61K31/4425; A61K31/47; A61K31/473; A61K31/55; A61K31/551; A61K31/5513; A61K31/66; A61K45/00; A61K45/06; A61P21/02; A61P25/08; A61P25/18; A61P25/20; A61P25/22; A61P39/02; A61P43/00; (IPC1-7): A61K31/00; A61K31/14; A61K31/405; A61K31/435; A61K31/44; A61K31/55; A61K31/66
Other References:
Anesthesia and Analgesia, vol. 56, no. 3, May-June 1977, G. FOSTER et al.: "Physostigmine reversal of diazepam-induced depression", pages 348-352, see pages 350-351
Anesthesiology, vol. 64, no. 2, February 1986, E. VATASHSKY et al.: "Mechanism of antagonism by physostigmine of acute flunitrazepam intoxication", pages 248-252, see page 248: "Summary", "Introduction"
Anesthesia and Analgesia, vol. 54, no. 5, September-October 1975, C.D. BLITT et al.: "Reversal of lorazepam delirium by physostigmine", pages 607-608, see complete article
Resuscitation, vol. 16/suppl., 1988, Elsevier Scientific Publishers Ireland Ltd, (IE), P.M. LAUVEN et al.: "Flumazenil (Ro 15-1788) and physostigmine", pages S41-S48, see pages S42-S48
Anesthesia and Analgesia, vol. 65, no. 6, June 1986, The International Anesthesia Research Society, W.E. HOFFMAN et al.: "Cerebrovascular and cerebral metabolic effects of physostigmine, midazolam, and a benzodiazepine antagonist", pages 639-644
Anesthesia and Analgesia, vol. 62, no. 7, July 1983, The International Anesthesia Research Society, U.A. PANDIT et al.: "Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam", pages 679-685
W. FORTH et al.: "Allgemeine und spezielle Pharmakologie und Toxikologie", 5th edition, pages 106-109, Wissenschaftsverlag, Mannheim, DE
Biological Psychiatry, vol. 18, no. 12, December 1983, Society of Biological Psychiatry, S.I. DEUTSCH et al.: "Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease, and normals", pages 1363-1373
Anesthesiology, vol. 64, no. 2, February 1986, E. VATASHSKY et al.: "Mechanism of antagonism by physostigmine of acute flunitrazepam intoxication", pages 248-252, see page 248: "Summary", "Introduction"
Anesthesia and Analgesia, vol. 54, no. 5, September-October 1975, C.D. BLITT et al.: "Reversal of lorazepam delirium by physostigmine", pages 607-608, see complete article
Resuscitation, vol. 16/suppl., 1988, Elsevier Scientific Publishers Ireland Ltd, (IE), P.M. LAUVEN et al.: "Flumazenil (Ro 15-1788) and physostigmine", pages S41-S48, see pages S42-S48
Anesthesia and Analgesia, vol. 65, no. 6, June 1986, The International Anesthesia Research Society, W.E. HOFFMAN et al.: "Cerebrovascular and cerebral metabolic effects of physostigmine, midazolam, and a benzodiazepine antagonist", pages 639-644
Anesthesia and Analgesia, vol. 62, no. 7, July 1983, The International Anesthesia Research Society, U.A. PANDIT et al.: "Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam", pages 679-685
W. FORTH et al.: "Allgemeine und spezielle Pharmakologie und Toxikologie", 5th edition, pages 106-109, Wissenschaftsverlag, Mannheim, DE
Biological Psychiatry, vol. 18, no. 12, December 1983, Society of Biological Psychiatry, S.I. DEUTSCH et al.: "Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease, and normals", pages 1363-1373
Download PDF:
Previous Patent: TREATMENT OF FATIGUE SYNDROME WITH CHOLINESTERASE INHIBITORS
Next Patent: ENZYME SYSTEMS
Next Patent: ENZYME SYSTEMS